Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New mRNA flu shot passes first safety check in early trial

NCT ID NCT05829356

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 31 times

Summary

This early-stage study tested a new mRNA-based flu vaccine in 159 adults aged 18-49 and 60+. The goal was to check safety and how well the vaccine triggers an immune response compared to a standard flu shot. Researchers looked for side effects and measured antibody levels in the blood.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA IMMUNIZATION are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Investigational Site Number : 0360001

    Morayfield, Queensland, 4506, Australia

  • Investigational Site Number : 0360002

    Camberwell, Victoria, 3124, Australia

  • Investigational Site Number : 0360003

    Adelaide, 5000, Australia

  • Investigational Site Number : 0360004

    Herston, Queensland, 4006, Australia

  • Investigational Site Number : 8260001

    London, London, City of, SW10 9NH, United Kingdom

  • Investigational Site Number : 8260002

    Leicester, Leicestershire, LE1 5WW, United Kingdom

  • Investigational Site Number : 8260003

    Sheffield, Sheffield, S10 2JF, United Kingdom

  • Investigational Site Number : 8260004

    London, London, City of, W12 0HS, United Kingdom

Conditions

Explore the condition pages connected to this study.